ArticleBMJ open2025

Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line treatment for advanced biliary tract cancer: perspectives from US and Chinese payers.

Can Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.